title: Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.
abstract: BACKGROUND
  Cyclosporine is a valuable option for the treatment of psoriasis. This report summarizes studies regarding the use of cyclosporine since the last guidelines were published in 1998.
  
  
  OBJECTIVE
  A task force of the National Psoriasis Foundation Medical Board was convened to evaluate treatment options. Our aim was to achieve a consensus on new updated guidelines for the use of cyclosporine in the treatment of psoriasis.
  
  
  METHODS
  Reports in the literature were reviewed regarding cyclosporine therapy.
  
  
  CONCLUSIONS
  There are few evidence-based studies on the treatment of psoriasis with cyclosporine.
  
  
  RESULTS
  A consensus was achieved on the use of cyclosporine in psoriasis including specific recommendations on dosing, monitoring, and use of cyclosporine in special situations. The consensus received approval from members of the National Psoriasis Foundation Medical Board.
  
  
  CONCLUSIONS
  Cyclosporine is a safe and effective drug for the treatment of psoriasis. It has a particularly useful role in managing psoriatic crises, treating psoriasis unresponsive to other modalities, bridging to other therapies, and treating psoriasis within a rotational scheme of other medications. Appropriate patient selection and monitoring will significantly decrease the risks of side effects.
authors.affiliation: Department of Dermatology at Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Rosmarin
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
authors.forename: Boni E
authors.initials: BE
authors.lastname: Elewski
authors.forename: Alice B
authors.initials: AB
authors.lastname: Gottlieb
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D000075202:Contraindications; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000150:complications; D019698:Hepatitis C, Chronic / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007674:Kidney Diseases / Q000139:chemically induced; D011247:Pregnancy; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D016572:Cyclosporine